Likewise, YAP/TAZ is known to drive tumor proliferation and resistance in response to a variety of targeted therapies, including EGFR, Anaplastic Lymphoma Kinase (ALK), Mitogen-activated protein kinase (MEK), and Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors [24,49,50,51,52]. This evidence concerns the gene YAP1 and neoplasm.